AI assistant
Nuvation Bio Inc. — Director's Dealing 2025
Nov 21, 2025
32154_dirs_2025-11-21_2e14c24e-dbe0-4b3f-ab2d-8199bbf4973a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Nuvation Bio Inc. (NUVB)
CIK: 0001811063
Period of Report: 2025-11-19
Reporting Person: Hanley David C. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-11-19 | Class A Common Stock | M | 200000 | $1.87 | Acquired | 224000 | Direct |
| 2025-11-19 | Class A Common Stock | S | 200000 | $7.1384 | Disposed | 24000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-11-19 | Stock Option (Right to Buy) | $1.87 | M | 200000 | Disposed | 2034-02-27 | Class A Common Stock (200000) | Direct |
Footnotes
F1: Includes 3,000 shares acquired on each of May 19, 2025 and November 19, 2025 under the Issuer's 2021 Employee Stock Purchase Plan.
F2: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $7.045 to $7.260. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3: Option vests as to 25% on the one year anniversary of 2/29/2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.